Positive results announced for two pivotal Phase-3 clinical trials of tildrakizumab in patients with moderate-to-severe plaque psoriasis

Sun Pharma has announced that two pivotal Phase-3 clinical trials evaluating the efficacy and safety of the investigational IL-23p19 inhibitor antibody tildrakizumab (MK-3222) in patients with...